Cancer Biotech Juno Eyes $204M IPO With Increased Terms
Cancer immunotherapy developer Juno Therapeutics Inc., which already was set to be the largest biotech listing of 2014 by diluted market capitalization, increased the size of its initial public offering Tuesday,...To view the full article, register now.
Already a subscriber? Click here to view full article